Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 12.

Samaras, P; Pfrommer, S; Seifert, B; Petrausch, U; Mischo, A; Schmidt, A; Schanz, U; Nair, G; Bargetzi, M; Taverna, C; Stupp, R; Stenner-Liewen, F; Renner, C (2015). Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma. Biology of Blood and Marrow Transplantation, 21(1):74-80.

Schuberth, P C; Jakka, G; Jensen, S M; Wadle, A; Gautschi, F; Haley, D; Haile, S; Mischo, A; Held, G; Thiel, M; Tinguely, M; Bifulco, C B; Fox, B A; Renner, C; Petrausch, U (2013). Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Therapy, 20(4):386-395.

Luehty, A; Stenner, F; Lohri, C; Muller, C; Samaras, P; Steiner, R; van den Broek, Maries; Mischo, A; Renner, C; Knuth, A; Ruegg, C; Wenger, R H; Zweifel, M (2011). Autologous Stem Cell Transplantation: Leukapheresis Product has Anti-angiogenic Effects In Vivo Correlating with Neutrophil-derived VEGFR1. Anticancer Research, 31(10):3115-3124.

Petrausch, U; Samaras, P; Mischo, A; Stenner, F; Tinguely, M; Schäfer, N; Studer, G; Renner, C (2011). Die Nachsorge beim Hodgkin-Lymphom. Praxis, 100(25):1515-1522.

Samaras, P; Blickenstorfer, M; Siciliano, R D; Haile, S R; Buset, E M; Petrausch, U; Mischo, A; Honegger, H; Schanz, U; Stüssi, G; Stahel, R A; Knuth, A; Stenner-Liewen, F; Renner, C (2011). Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Annals of Hematology, 90(1):89-94.

Mischo, A; Bubel, N; Cebon, J S; Samaras, P; Petrausch, U; Stenner-Liewen, F; Schaefer, N G; Kubuschok, B; Renner, C; Wadle, A (2011). Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis. International Journal of Oncology, 39(1):287-294.

Samaras, P; Blickenstorfer, M; Haile, S R; Siciliano, D; Petrausch, U; Mischo, A; Zweifel, M; Honegger, H; Schanz, U; Stüssi, G; Taverna, C; Bauer, S; Knuth, A; Stenner-Liewen, F; Renner, C (2011). Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. Swiss Medical Weekly, 141:w13203.

Petrausch, U; Samaras, P; Haile, S R; Veit-Haibach, P; Soyka, J D; Knuth, A; Hany, T F; Mischo, A; Renner, C; Schäefer, N G (2010). Risk adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first line therapy. Annals of Oncology, 21(8):1694-1698.

Petrausch, U; Samaras, P; Veit-Haibach, P; Tschopp, A; Soyka, J D; Knuth, A; Hany, T F; Mischo, A; Renner, C; Schaefer, N G (2010). Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Annals of Oncology, 21(5):1053-1057.

Samaras, P; Heider, H; Haile, S R; Petrausch, U; Schaefer, N G; Siciliano, R D; Meisel, A; Mischo, A; Zweifel, M; Knuth, A; Stenner-Liewen, F; Renner, C (2010). Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Annals of Hematology, 89(8):783-787.

Samaras, P; Buset, E M; Siciliano, R D; Haile, S R; Petrausch, U; Mischo, A; Honegger, H; Pestalozzi, B C; Schanz, U; Stüssi, G; Stahel, R A; Knuth, A; Renner, C; Stenner-Liewen, F (2010). Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation. Oncology, 79(1-2):93-97.

Wadle, A; Mischo, A; Strahl, S; Nishikawa, H; Held, G; Neumann, F; Wullner, B; Fischer, E; Kleber, S; Karbach, J; Jager, E; Shiku, H; Odunsi, K; Shrikant, P A; Knuth, A; Cerundolo, V; Renner, C (2010). NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses. FEMS Yeast Research, 27(11):919-931.

This list was generated on Sat Nov 25 02:56:26 2017 CET.